Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: A population-based study

European Respiratory Journal

Volumn 50, Issue 1, 2017, Pages

  Weatherald, Jason ^a,b,c,d   Chaumais, Marie Camille ^a,c,e   Savale, Laurent ^a,b,c   Jaïs, Xavier ^a,b,c   Seferian, Andrei ^a,b,c   Canuet, Matthieu ^f   Bouvaist, Hélène ^g   Magro, Pascal ^h   Bergeron, Anne ^i,j   Guignabert, Christophe ^a,c   Sitbon, Olivier ^a,b,c   Simonneau, Gérald ^a,b,c   Humbert, Marc ^a,b,c   Montani, David ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d UNIVERSITY OF CALGARY   (Canada)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

^f HÔPITAL CIVIL   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF TOURS   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j PARIS DESCARTES UNIVERSITY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSUTINIB; CALCIUM CHANNEL BLOCKING AGENT; CYTARABINE; DASATINIB; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; PHOSPHODIESTERASE V INHIBITOR; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BMPR2 GENE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MASTOCYTOSIS; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; PROGNOSIS; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SIX MINUTE WALK TEST; TREATMENT DURATION; CHEMICALLY INDUCED; FRANCE; KAPLAN MEIER METHOD; MIDDLE AGED; REGISTER; VASCULAR RESISTANCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DASATINIB; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; REGISTRIES; RETROSPECTIVE STUDIES; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 85026861721     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00217-2017     Document Type: Article

References (36)

1. Galie N, Humbert M, Vachiéry J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903-975.
2. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34-D41.
3. Guignabert C, Tu L, Girerd B, et al. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension. Chest 2015; 147: 529-537.
4. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
5. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients trial. J Clin Oncol 2016; 34: 2333-2340.
6. US Food and Drug Administration. Sprycel (dasatinib) prescribing and labeling information. www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf Date last accessed January 10, 2017.
7. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49: 615-619.
8. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
9. Riou M, Seferian A, Savale L, et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. Eur Respir J 2016; 48: 1517-1519.
10. Hickey PM, Thompson AA, Charalampopoulos A, et al. Bosutinib therapy resulting in deterioration of pre-existing pulmonary arterial hypertension. Eur Respir J 2016; 48: 1514-1516.
11. Quilot F-M, Georges M, Favrolt N, et al. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J 2016; 47: 676-679.
12. Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055-4063.
13. Winter GE, Rix U, Carlson SM, et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol 2012; 8: 905-912.
14. Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 2015; 90: 1060-1064.
15. Herve P, Lau EM, Sitbon O, et al. Criteria for diagnosis of exercise pulmonary hypertension. Eur Respir J 2015; 46: 728-737.
16. Morishita S, Hagihara M, Itabashi M, et al. Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia. Rinsho Ketsueki 2016; 57: 999-1003.
17. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009; 33: 861-864.
18. Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009; 43: 967-968.
19. Groeneveldt JA, Gans SJM, Bogaard HJ, et al. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. Eur Respir J 2013; 42: 869-870.
20. Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 2016; 126: 3207-3218.
21. Savale L, Sattler C, Günther S, et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 2014; 44: 1627-1634.
22. Savale L, Chaumais MC, Sitbon O, et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J 2015; 46: 1851-1853.
23. Savale L, Chaumais MC, O'Connell C, et al. Interferon-induced pulmonary hypertension: an update. Curr Opin Pulm Med 2016; 22: 415-420.
24. Perros F, Montani D, Dorfmüller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81-88.
25. Montani D, Perros F, Gambaryan N, et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011; 184: 116-123.
26. Ghofrani H, Morrell N, Hoeper M, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.
27. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127: 1128-1138.
28. Swords R, Mahalingam D, Padmanabhan S, et al. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 2009; 3: 89-101.
29. Snead JL, O'Hare T, Adrian LT, et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009; 114: 3459-3463.
30. Wang X, Roy A, Hochhaus A, et al. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol 2013; 5: 85-97.
31. Shah NP, Kantarjian HM, Kim D-W, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204-3212.
32. Jutant E-M, Phan C, Tu L, et al. Dasatinib causes pulmonary endothelial damage and increases endothelial permeability. Am J Respir Crit Care Med 2016; 193: A2797.
33. Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010; 116: 377-386.
34. Kitagawa D, Yokota K, Gouda M, et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 2013; 18: 110-122.
35. Josephs DH, Fisher DS, Spicer J, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug Monit 2013; 35: 562-587.
36. Nagaraj C, Tang B, Balint Z, et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J 2013; 41: 85-95.